Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RT-111 (ustekinumab-biosimilar) is an oral anti-IL 12/23 antibody. It is being evaluated in phase 1 clinical trials for the treatment of of moderate to severe plaque psoriasis, Crohn’s disease, ulcerative colitis & active psoriatic arthritis.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: RT-111
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
Incretin triagonist of the GLP-1, GIP, and glucagon receptors delivered transenterically, which mimics the RaniPill route of administration to enable oral delivery of multiple obesity treatments.
Lead Product(s): Incretin-based Triagonist
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
RT-105 (adalimumab) is a monoclonal antibody which inhibits tumor necrosis factor. It binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: RT-105
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2023
Details:
RT-111 (ustekinumab) is an orally administered RaniPill®GO capsule containing an ustekinumab biosimilar that act as binds with specificity to the p40 protein subunit used by both the interleukin-12 and interleukin-23 for the treatment of psorasis.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: RT-111
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Under the agreement, Celltrion will exclusively supply to Rani the adalimumab biosimilar drug substance (CT-P17) required for the development of RT-105, an oral capsule containing a TNF-α inhibitor antibody being developed for the treatment of psoriatic arthritis.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: RT-105
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Celltrion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 05, 2023
Details:
Rani is granted an exclusive license to use CT-P43 in the development and commercialization of RT-111, an orally administered ustekinumab biosimilar and Celltrion is granted a right of first negotiation to acquire worldwide rights to RT-111 following a Phase 1 clinical trial.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: RT-111
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Celltrion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 09, 2023
Details:
RT-102 (Parathyroid Hormone) is being developed for the treatment of osteoporosis. The study achieved all of its endpoints, with repeat doses of RT-102 being generally well tolerated and delivering drug with high reliability to participants via the RaniPill™ GO.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: RT-102
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
The study achieved all of its endpoints, with repeat doses of RT-102 (parathyroid hormone) being generally well tolerated and delivering drug with high reliability to participants via the RaniPill™ GO.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: RT-102
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
RT-111, a RaniPill GO capsule containing a biosimilar of STELARA® (ustekinumab) is an interleukin-12 and interleukin-23 antagonist for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis.
Lead Product(s): Ustekinumab
Therapeutic Area: Endocrinology Product Name: RT-111
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
RT-102, RaniPill capsule containing proprietary formulation of human PTH analog PTH (1-34) for potential treatment of osteoporosis achieved all of its endpoints, with RT-102 being generally well-tolerated and demonstrating high oral bioavailability of Rani’s PTH analog.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: RT-102
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022